The growing focus on preventive healthcare solutions to drive the growth of the Recombinant Vaccine Market.


The recombinant vaccine market is estimated to be valued at US$ 1,184.29 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Recombinant vaccines are produced through genetic engineering techniques by combining genetic material from pathogens that induce a strong immune response in the host. Recombinant vaccines are beneficial as they are more stable and consistent in quality and purity compared to live attenuated and inactivated vaccines. Due to advancements in gene technology, several recombinant vaccines have been developed for diseases such as hepatitis B, human papillomavirus, and others. They are also useful for diseases where conventional vaccine development has limitations.

Market Dynamics:
Advancing gene technology: Advances in genetic engineering and cell line technologies have enabled the development of efficient recombinant protein expression systems for rapid and high-volume production of recombinant vaccines. This has led to an increasing pipeline of recombinant vaccine candidates.

Growing disease burden: The growing disease burden of various infectious and non-communicable diseases globally is driving the demand for new and affordable vaccines. Recombinant vaccine production methods allow for cost-effective mass production to meet this rising demand.
Segment Analysis

The recombinant vaccine market is segmented based on the technology into viral vector vaccine, DNA vaccine, recombinant protein vaccine and others. Among these, the recombinant protein vaccine segment dominated the market in 2019 and is expected to maintain its dominance over the forecast period. Recombinant protein vaccines involve expression of immunogenic pathogen proteins in heterologous gene expression systems. They are relatively stable, easy to manufacture and safe to administer. This makes recombinant protein vaccines an affordable and effective option.

PEST Analysis

Political: Government support for vaccine research and development through funding and initiatives has been increasing globally. For instance, the US government invested over $10 billion in 2020 for COVID-19 vaccine development through Operation Warp Speed program.

Economic: The global recombinant vaccine market size was valued at $1,184.29 Million in 2023 and is projected to reach $2,089.07 Million by 2030, exhibiting a CAGR of 6.1%. Growing disease burden and demand for affordable prophylactic measures are driving market growth.

Social: Rising awareness about the benefits of vaccination and importance of fulfilling basic healthcare needs are positively impacting the market. New vaccine introductions are expanding population coverage against infectious diseases.

Technological: Advances in genetic engineering and cell culture technology have enabled rapid development and production of recombinant vaccines. Automation in manufacturing and quality control testing have further increased yields and process efficiencies.

Key Takeaways

The global recombinant vaccine market is expected to witness high growth, exhibiting CAGR of 6.1% over the forecast period, due to increasing disease prevalence and demand for affordable preventive healthcare. By 2030, the market size is projected to reach $2,089.07 Mn.

The Asia Pacific region is emerging as the fastest growing market for recombinant vaccines. Countries like India, China and Indonesia have high disease burden as well as growing demand for affordable vaccination, which is driving market expansion in the region.

Key players operating in the recombinant vaccine market are Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, GSK plc., GC Biopharma, Bayer AG, Bharat Biotech, Serum Institute of India Pvt. Ltd., Sartorius AG, Johnson & Johnson Services, Inc., and Bio Farma. These players are focusing on partnerships, acquisitions and new product launches to strengthen their market presence. For instance, in 2020, Merck announced collaboration with IAVI to develop monoclonal antibody treatment for COVID-19.